We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VEVYE (AFT Pharmaceuticals Pty Ltd)
Product name
VEVYE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
ciclosporin
Registration type
EOI
Indication
Vevye® is indicated in adult patients for the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) which has not improved despite treatment with tear substitutes (see section 5.1 Pharmacodynamic Properties – Clinical Trials).